ClinicalTrials.Veeva

Menu

Impact of Pharmaceutical Interviews Regarding the Management of Adverse Effects Related to the Antibiotic Therapy Used to Treat Osteoarticular Infections During Return Home (EFIRAD)

A

Assistance Publique - Hôpitaux de Paris

Status

Completed

Conditions

Bone and Joint Infection

Treatments

Other: pharmaceutical interview

Study type

Interventional

Funder types

Other

Identifiers

NCT05248490
APHP211422
2021-A02433-38 (Registry Identifier)

Details and patient eligibility

About

The primary objective is to evaluate the impact of Pharmaceutical Interviews in the patient self-management of non-severe side effects caused by antibiotics prescribed for the treatment of osteoarticular infections when the patient returns home.

Enrollment

90 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient > or =18 years;
  • Informed consent signed;
  • French-speaking and reading;
  • Affiliated to a social insurance;
  • Benefiting from medical and surgical care for an osteoarticular infection;
  • Treated with an oral antibiotic therapy on discharge from hospital.
  • Indication of the antibiotic therapy osteoarticular infection;
  • Return home immediately after discharge.

Exclusion criteria

  • Refusal to participate
  • Protected adult patient, under guardianship or curatorship.
  • Minor patient
  • Patient benefiting from an AME.
  • Pregnant or breastfeeding woman.
  • Non-French speaking patient.
  • Patient unable to understand the course of the study.
  • Patient with a documented history of cognitive or psychiatric disorders.
  • Patient treated with oral antibiotic therapy for an indication other than osteoarticular infection.
  • Patient treated with parenteral antibiotic therapy.
  • Discharge: Institution (EHPAD), rehabilitation or other health establishment.
  • Patient systematically using one of the symptomatic treatments proposed in the discharge prescription before hospitalization.

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

90 participants in 2 patient groups

Patients with pharmaceutical interview
Experimental group
Description:
Pharmaceutical interview with pharmacist: to be informed treatment taken and related SAE informations at the end of hospitalization.
Treatment:
Other: pharmaceutical interview
Patients without pharmaceutical interview
No Intervention group
Description:
Control group without interview

Trial contacts and locations

1

Loading...

Central trial contact

Thomas Tritz, PharmD; Manon Deschamps

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems